2024
Association of Sacubitril/Valsartan versus Valsartan with Blood Pressure Changes, and Symptomatic Hypotension: The PARAGLIDE-HF Trial
Fudim M, Cyr D, Ward J, Hernandez A, Lepage S, Morrow D, Sharma K, Claggett B, Starling R, Velazquez E, Williamson K, Desai A, Zieroth S, Solomon S, Braunwald E, Mentz R, Investigators P. Association of Sacubitril/Valsartan versus Valsartan with Blood Pressure Changes, and Symptomatic Hypotension: The PARAGLIDE-HF Trial. Journal Of Cardiac Failure 2024 PMID: 38802053, DOI: 10.1016/j.cardfail.2024.04.030.Peer-Reviewed Original ResearchLeft ventricular ejection fractionWorsening heart failureBaseline systolic blood pressureSystolic blood pressureVentricular ejection fractionEjection fractionSymptomatic hypotensionNT-proBNPHeart failureBlood pressureLow baseline systolic blood pressureTime-averaged proportional changeMildly reduced ejection fractionPlasma NT-proBNP levelsAssociated with clinical benefitB-type natriuretic peptideNT-proBNP levelsReduced ejection fractionMedian blood pressureBlood pressure changesSH eventsTime-averaged changePrimary endpointNatriuretic peptideRandomized patientsTorsemide Versus Furosemide After Discharge in Patients Hospitalized With Heart Failure Across the Spectrum of Ejection Fraction: Findings From TRANSFORM-HF
Kapelios C, Greene S, Mentz R, Ikeaba U, Wojdyla D, Anstrom K, Eisenstein E, Pitt B, Velazquez E, Fang J, Investigators T. Torsemide Versus Furosemide After Discharge in Patients Hospitalized With Heart Failure Across the Spectrum of Ejection Fraction: Findings From TRANSFORM-HF. Circulation Heart Failure 2024, 17: e011246. PMID: 38436075, PMCID: PMC10950535, DOI: 10.1161/circheartfailure.123.011246.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionLVEF groupsKansas City Cardiomyopathy Questionnaire Clinical Summary ScoreMildly reduced left ventricular ejection fractionBaseline left ventricular ejection fractionReduced left ventricular ejection fractionClinical summary scoreHeart failureNo significant differenceEjection fractionClinical outcomesLVEF spectrumSignificant differenceLeft ventricular ejection fraction dataEnd pointsSpectrum of ejection fractionEffect of torsemideRisk of clinical outcomesVentricular ejection fractionStudy end pointBaseline patient characteristicsClinical end pointsSummary scoreAll-cause mortalityPrevalence of comorbiditiesSacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure
Morrow D, Velazquez E, Desai A, DeVore A, Lepage S, Park J, Sharma K, Solomon S, Starling R, Ward J, Williamson K, Zieroth S, Hernandez A, Mentz R, Braunwald E. Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure. Journal Of The American College Of Cardiology 2024, 83: 1123-1132. PMID: 38508844, DOI: 10.1016/j.jacc.2024.01.027.Peer-Reviewed Original ResearchConceptsWorsening heart failureHeart failureEjection fractionNT-proBNPSpectrum of EFPIONEER-HFSpectrum of left ventricular ejection fractionRandomized trialsTime-averaged proportional changeN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideLeft ventricular ejection fractionWorsening heart failure eventDecompensated heart failureVentricular ejection fractionPlasma NT-proBNPPIONEER-HF trialDouble-blindMedian ageMedian EFSNatriuretic peptideSymptomatic hypotensionBaseline characteristicsClinical outcomesPooled analysisFactors associated with reporting left ventricular ejection fraction with 3D echocardiography in real‐world practice
Faridi K, Zhu Z, Shah N, Crandall I, McNamara R, Flueckiger P, Bachand K, Lombo B, Hur D, Agarwal V, Reinhardt S, Velazquez E, Sugeng L. Factors associated with reporting left ventricular ejection fraction with 3D echocardiography in real‐world practice. Echocardiography 2024, 41: e15774. PMID: 38329886, DOI: 10.1111/echo.15774.Peer-Reviewed Original ResearchConceptsTransthoracic echocardiogramVentricular ejection fractionOutpatient transthoracic echocardiogramsReal-world practiceEjection fractionLeft ventricular ejection fractionAssess left ventricular ejection fractionInpatient transthoracic echocardiogramsMultivariate logistic regressionLVEFHospitalized patientsMedical CenterSonographersClinical settingLogistic regressionUltrasound machineChemotherapyContrast enhancement agentsPortable studiesNegative association
2023
Predicting aortic stenosis progression using a video-based deep learning model of aortic stenosis built for single-view two-dimensional echocardiography
Oikonomou E, Holste G, Mcnamara R, Velazquez E, Nadkarni G, Ouyang D, Krumholz H, Wang Z, Khera R. Predicting aortic stenosis progression using a video-based deep learning model of aortic stenosis built for single-view two-dimensional echocardiography. European Heart Journal 2023, 44: ehad655.040. DOI: 10.1093/eurheartj/ehad655.040.Peer-Reviewed Original ResearchLeft ventricular ejection fractionSevere aortic stenosisAortic stenosisAS progressionAV VmaxTransthoracic echocardiographyYale New Haven Health SystemBaseline left ventricular ejection fractionAortic stenosis progressionModerate aortic stenosisRetrospective cohort studyVentricular ejection fractionTwo-dimensional echocardiographyMean rateModerate ASAS severityCohort studyEjection fractionPatient sexStenosis progressionTTE studiesEligible participantsSerial monitoringSpecialized centersTimely diagnosisSacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF
Vaduganathan M, Mentz R, Claggett B, Miao Z, Kulac I, Ward J, Hernandez A, Morrow D, Starling R, Velazquez E, Williamson K, Desai A, Zieroth S, Lefkowitz M, McMurray J, Braunwald E, Solomon S. Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. European Heart Journal 2023, 44: 2982-2993. PMID: 37210743, PMCID: PMC10424880, DOI: 10.1093/eurheartj/ehad344.Peer-Reviewed Original ResearchConceptsSacubitril/valsartanRenal composite endpointPARAGON-HFHeart failureEjection fractionPooled analysisHF eventsRenal eventsCardiovascular deathComposite endpointLeft ventricular ejection fractionVentricular ejection fractionActive-controlled trialParticipant-level dataPrimary endpointSecondary endpointsClinical outcomesNatriuretic peptideLike patientsTreatment benefitCare settingsPatientsPrimary analysisLVEFValsartan
2021
Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy
Farsky PS, White J, Al-Khalidi HR, Sueta CA, Rouleau J, Panza J, Velazquez E, O'Connor C, Investigators W, Dabrowski R, Djokovic L, Drazner M, Haddad H, Ali I, Keltai M, Naik A, Sopko G, Golba K, Andersson B, Carson P, Kukulski T. Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy. Journal Of Thoracic And Cardiovascular Surgery 2021, 164: 1890-1899.e4. PMID: 33610365, PMCID: PMC8260609, DOI: 10.1016/j.jtcvs.2020.12.094.Peer-Reviewed Original ResearchConceptsOptimal medical therapyCoronary artery bypassMedical therapyArtery bypassIschemic cardiomyopathyCause mortalityIschemic Heart Failure (STICH) trialVentricular ejection fraction 35Improved long-term survivalEjection fraction 35Angiotensin receptor blockersHeart Failure TrialLower cardiovascular mortalityMultivariable Cox modelOutcomes of patientsVentricular ejection fractionCoronary artery diseaseLong-term outcomesLong-term survivalSurgical revascularizationReceptor blockersCardiovascular mortalityAntiplatelet drugsArtery diseaseEjection fraction
2019
Percutaneous coronary intervention outcomes in patients with stable coronary disease and left ventricular systolic dysfunction
DeVore AD, Yow E, Krucoff MW, Sherwood MW, Shaw LK, Chiswell K, O'Connor CM, Ohman EM, Velazquez EJ. Percutaneous coronary intervention outcomes in patients with stable coronary disease and left ventricular systolic dysfunction. ESC Heart Failure 2019, 6: 1233-1242. PMID: 31560171, PMCID: PMC6989282, DOI: 10.1002/ehf2.12510.Peer-Reviewed Original ResearchConceptsStable coronary artery diseasePercutaneous coronary interventionCoronary artery diseaseVentricular systolic dysfunctionSevere left ventricular systolic dysfunctionLeft ventricular systolic dysfunctionSystolic dysfunctionMedical therapyCardiovascular hospitalizationAddition of PCICanadian Cardiovascular Society class IIIImpact of PCIPercutaneous coronary intervention outcomesDuke University Medical CenterComposite of mortalityPropensity-matched cohortStable coronary diseaseAcute coronary syndromeHigh-risk patientsLong-term mortalityVentricular ejection fractionCox proportional hazardsUniversity Medical CenterCause mortalityCoronary syndromeCABG Improves Outcomes in Patients With Ischemic Cardiomyopathy 10-Year Follow-Up of the STICH Trial
Howlett JG, Stebbins A, Petrie MC, Jhund PS, Castelvecchio S, Cherniavsky A, Sueta CA, Roy A, Piña IL, Wurm R, Drazner MH, Andersson B, Batlle C, Senni M, Chrzanowski L, Merkely B, Carson P, Desvigne-Nickens PM, Lee KL, Velazquez EJ, Al-Khalidi HR, Investigators S. CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy 10-Year Follow-Up of the STICH Trial. JACC Heart Failure 2019, 7: 878-887. PMID: 31521682, PMCID: PMC7375257, DOI: 10.1016/j.jchf.2019.04.018.Peer-Reviewed Original ResearchConceptsRecurrent event analysisSTICH trialCause hospitalizationCause-specific hospitalizationsNon-CV eventsTotal cardiovascular hospitalizationsCoronary artery bypassVentricular ejection fractionCABG groupCause deathHF hospitalizationArtery bypassCardiovascular causesCardiovascular hospitalizationEjection fractionHeart failureIschemic cardiomyopathyRecurrent hospitalizationsMost hospitalizationsEvent analysisHospitalizationPatientsCABGRecurrent eventsTotalMyocardial Viability and Long-Term Outcomes in Ischemic Cardiomyopathy
Panza JA, Ellis AM, Al-Khalidi HR, Holly TA, Berman DS, Oh JK, Pohost GM, Sopko G, Chrzanowski L, Mark DB, Kukulski T, Favaloro LE, Maurer G, Farsky PS, Tan RS, Asch FM, Velazquez EJ, Rouleau JL, Lee KL, Bonow RO. Myocardial Viability and Long-Term Outcomes in Ischemic Cardiomyopathy. New England Journal Of Medicine 2019, 381: 739-748. PMID: 31433921, PMCID: PMC6814246, DOI: 10.1056/nejmoa1807365.Peer-Reviewed Original ResearchMeSH KeywordsAgedCoronary Artery BypassEchocardiography, StressFemaleFollow-Up StudiesHeartHumansIncidenceKaplan-Meier EstimateMaleMiddle AgedMyocardial IschemiaProportional Hazards ModelsProspective StudiesStroke VolumeTomography, Emission-Computed, Single-PhotonTreatment OutcomeVentricular Function, LeftConceptsLeft ventricular ejection fractionVentricular ejection fractionMedical therapyEjection fractionMyocardial viabilityIschemic cardiomyopathyLeft ventricular systolic functionGoals of revascularizationCoronary artery bypassPrimary end pointVentricular systolic functionCoronary artery diseaseLeft ventricular functionLong-term outcomesLong-term survivalSurgical revascularizationDobutamine echocardiographyMedian durationSystolic functionArtery diseaseVentricular functionViable myocardiumLong-term benefitsLower incidenceCABGRepresentativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized with Heart Failure
Sayeed S, Fudim M, Xu H, Matsouaka R, Heidenreich P, Yancy C, Fonarow G, Velazquez E, Hernandez A, DeVore A. Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized with Heart Failure. Journal Of Cardiac Failure 2019, 25: s151. DOI: 10.1016/j.cardfail.2019.07.436.Peer-Reviewed Original ResearchAcute decompensated heart failurePIONEER-HF trialSacubitril/valsartanHFrEF patientsCause mortalityEjection fractionEligible cohortHeart failureLeft ventricular ejection fractionGWTG-HF registryHF rehospitalization ratesDecompensated heart failureReduced ejection fractionInitial study populationVentricular ejection fractionClinical trial populationsLong-term outcomesDaily clinical practiceTrial eligibility criteriaGWTG-HFHF hospitalizationHospital initiationPIONEER-HFHF readmissionIndex dischargeDoes prior coronary angioplasty affect outcomes of surgical coronary revascularization? Insights from the STICH trial
Nicolau JC, Stevens SR, Al-Khalidi HR, Jatene FB, Furtado RHM, Dallan LAO, Lisboa LAF, Desvigne-Nickens P, Haddad H, Jolicoeur EM, Petrie MC, Doenst T, Michler RE, Ohman EM, Maddury J, Ali I, Deja MA, Rouleau JL, Velazquez EJ, Hill JA. Does prior coronary angioplasty affect outcomes of surgical coronary revascularization? Insights from the STICH trial. International Journal Of Cardiology 2019, 291: 36-41. PMID: 30929973, PMCID: PMC6579621, DOI: 10.1016/j.ijcard.2019.03.029.Peer-Reviewed Original ResearchConceptsPrior percutaneous coronary interventionPercutaneous coronary interventionLeft ventricular ejection fractionSTICH trialCV hospitalizationCV mortalityCause mortalityMedical treatmentSuperiority of CABGOutcomes of patientsSurgical coronary revascularizationCoronary artery bypassVentricular ejection fractionArtery bypassCoronary revascularizationCoronary interventionCoronary angioplastyEjection fractionMedian timeWorse prognosisRandomized treatmentCABGHospitalizationMortalityPatientsSpeckle Tracking Analysis of Left Ventricular Systolic Function Following Traumatic Brain Injury: A Pilot Prospective Observational Cohort Study
Krishnamoorthy V, Chaikittisilpa N, Lee J, Mackensen GB, Gibbons EF, Laskowitz D, Hernandez A, Velazquez E, Lele AV, Vavilala MS. Speckle Tracking Analysis of Left Ventricular Systolic Function Following Traumatic Brain Injury: A Pilot Prospective Observational Cohort Study. Journal Of Neurosurgical Anesthesiology 2019, 32: 156-161. PMID: 30676403, PMCID: PMC6646112, DOI: 10.1097/ana.0000000000000578.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionGlobal longitudinal strainTraumatic brain injuryAge/sex-matched controlsSex-matched controlsModerate-severe traumatic brain injurySystolic dysfunctionCohort studyBrain injuryMean global longitudinal strainProspective observational cohort studyObservational cohort studyProspective cohort studySubclinical myocardial dysfunctionVentricular ejection fractionSpeckle trackingSpeckle tracking analysisFirst dayMid-ventricular segmentsModerate-severe TBI patientsSystolic functionTransthoracic echocardiographyEjection fractionMyocardial dysfunctionTBI patients
2018
Childhood and adult exposure to secondhand tobacco smoke and cardiac structure and function: results from Echo-SOL
Peña M, Swett K, Kaplan RC, Perreira K, Daviglus M, Kansal MM, Cai J, Giachello AL, Gellman MD, Velazquez EJ, Rodriguez CJ. Childhood and adult exposure to secondhand tobacco smoke and cardiac structure and function: results from Echo-SOL. Open Heart 2018, 5: e000831. PMID: 30402256, PMCID: PMC6203071, DOI: 10.1136/openhrt-2018-000831.Peer-Reviewed Original ResearchLeft ventricular global longitudinal strainLeft ventricular ejection fractionIsovolumic relaxation timeSHS exposureCardiac structureTobacco smokersRight ventricular fractional area changeVentricular global longitudinal strainVentricular fractional area changeHousehold SHS exposureAtrial volume indexClinical heart failureSevere valvular diseaseVentricular ejection fractionCoronary artery diseaseGlobal longitudinal strainSecondhand smoke exposureFractional area changeHousehold secondhand smoke exposureAdolescents/adultsECHO-SOLArtery diseaseCardiac systolicDiastolic functionEchocardiographic measuresA meta‐analysis of MitraClip combined with medical therapy vs. medical therapy alone for treatment of mitral regurgitation in heart failure patients
Giannini C, D'ascenzo F, Fiorelli F, Spontoni P, Swaans MJ, Velazquez EJ, Armeni P, Adamo M, De Carlo M, Petronio AS. A meta‐analysis of MitraClip combined with medical therapy vs. medical therapy alone for treatment of mitral regurgitation in heart failure patients. ESC Heart Failure 2018, 5: 1150-1158. PMID: 30191666, PMCID: PMC6300824, DOI: 10.1002/ehf2.12339.Peer-Reviewed Original ResearchConceptsFunctional mitral regurgitationMedical therapyMitral regurgitationSurvival benefitConservative treatmentPercutaneous mitral valve repairEffect of MitraClipRobust survival benefitSignificant survival benefitCardiac resynchronization therapyEligible observational studiesHeart failure patientsVentricular ejection fractionMitral valve repairPatient-level analysisComprehensive literature searchStudy-level analysisConservative therapyIschemic etiologyPrimary endpointFailure patientsMultivariate adjustmentEjection fractionResynchronization therapySurvival outcomesTranscatheter Aortic Valve Replacement versus Medical Management among Patients with Aortic Stenosis and Left Ventricular Systolic Dysfunction
Lowenstern A, Vora A, Dunning A, Schulte P, Vemulapalli S, Hughes G, Velazquez E, Harrison J, Samad Z. Transcatheter Aortic Valve Replacement versus Medical Management among Patients with Aortic Stenosis and Left Ventricular Systolic Dysfunction. Structural Heart 2018, 2: 388-395. DOI: 10.1080/24748706.2018.1500049.Peer-Reviewed Original ResearchTranscatheter aortic valve replacementCoronary artery bypass graftSevere aortic stenosisVentricular systolic dysfunctionAortic valve replacementAortic stenosisMedical managementSystolic dysfunctionValve replacementOutcomes of patientsArtery bypass graftVentricular ejection fractionIschemic heart diseaseCause mortalityMultivariable adjustmentRenal insufficiencyTAVR patientsTransthoracic echocardiogramEjection fractionHeart failureMedian ageBypass graftHistorical cohortTherapeutic optionsPatient populationVariability in Ejection Fraction Measured By Echocardiography, Gated Single-Photon Emission Computed Tomography, and Cardiac Magnetic Resonance in Patients With Coronary Artery Disease and Left Ventricular Dysfunction
Pellikka PA, She L, Holly TA, Lin G, Varadarajan P, Pai RG, Bonow RO, Pohost GM, Panza JA, Berman DS, Prior DL, Asch FM, Borges-Neto S, Grayburn P, Al-Khalidi HR, Miszalski-Jamka K, Desvigne-Nickens P, Lee KL, Velazquez EJ, Oh JK. Variability in Ejection Fraction Measured By Echocardiography, Gated Single-Photon Emission Computed Tomography, and Cardiac Magnetic Resonance in Patients With Coronary Artery Disease and Left Ventricular Dysfunction. JAMA Network Open 2018, 1: e181456-e181456. PMID: 30646130, PMCID: PMC6324278, DOI: 10.1001/jamanetworkopen.2018.1456.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionCoronary artery diseaseCardiovascular magnetic resonanceVentricular ejection fractionArtery diseaseCore laboratorySingle photon emissionVentricular dysfunctionEjection fractionBland-Altman plotsLVEF measurementsAssociation of LVEFGated single-photon emissionIschemic heart failureLeft ventricular dysfunctionSubset of patientsOptimal treatment strategyImaging modalitiesMulticenter diagnostic studyCardiac magnetic resonanceInternational multicenter studyLVEF dataMost patientsHeart failureSurgical treatmentThe relationship between baseline and follow-up left ventricular ejection fraction with adverse events among primary prevention ICD patients
Friedman DJ, Fudim M, Overton R, Shaw LK, Patel D, Pokorney SD, Velazquez EJ, Al-Khatib SM. The relationship between baseline and follow-up left ventricular ejection fraction with adverse events among primary prevention ICD patients. American Heart Journal 2018, 201: 17-24. PMID: 29910051, PMCID: PMC6309220, DOI: 10.1016/j.ahj.2018.03.017.Peer-Reviewed Original ResearchConceptsLeft ventricular assist devicePrimary prevention ICD patientsAppropriate ICD therapyVentricular ejection fractionImplantable cardioverter defibrillatorICD therapyICD implantationEjection fractionICD patientsMultivariable Cox proportional hazards modelsPrimary prevention implantable cardioverter defibrillatorsCo-primary study endpointsPrimary prevention ICD recipientsFollow-up left ventricular ejection fractionLeft ventricular ejection fractionCox proportional hazards modelComposite of timeLong-term followProportional hazards modelVentricular assist deviceLong-term riskBaseline LVEFLVEF improvementAdverse eventsComposite endpointSex Difference in Patients With Ischemic Heart Failure Undergoing Surgical Revascularization
Piña IL, Zheng Q, She L, Szwed H, Lang IM, Farsky PS, Castelvecchio S, Biernat J, Paraforos A, Kosevic D, Favaloro LE, Nicolau JC, Varadarajan P, Velazquez EJ, Pai RG, Cyrille N, Lee KL, Desvigne-Nickens P. Sex Difference in Patients With Ischemic Heart Failure Undergoing Surgical Revascularization. Circulation 2018, 137: 771-780. PMID: 29459462, PMCID: PMC5896331, DOI: 10.1161/circulationaha.117.030526.Peer-Reviewed Original ResearchConceptsIschemic left ventricular dysfunctionLeft ventricular dysfunctionCause mortalityCardiovascular mortalitySTICH trialSurgical deathsVentricular dysfunctionCardiovascular hospitalizationRisk factorsKansas City Cardiomyopathy Questionnaire overall summary scoreHigher New York Heart Association classCardiac Operative Risk Evaluation scoreCoronary artery disease risk factorsNew York Heart Association classHigher body mass indexComposite of deathCoronary artery bypassIschemic heart failureDisease risk factorsPoor prognostic factorVentricular ejection fractionCoronary artery diseaseBody mass indexLong-term outcomesOverall summary scoreSix-minute walk distance after coronary artery bypass grafting compared with medical therapy in ischaemic cardiomyopathy
Stewart RAH, Szalewska D, Stebbins A, Al-Khalidi HR, Cleland JGH, Rynkiewicz A, Drazner MH, White HD, Mark DB, Roy A, Kosevic D, Rajda M, Jasinski M, Leng CY, Tungsubutra W, Desvigne-Nickens P, Velazquez EJ, Petrie MC. Six-minute walk distance after coronary artery bypass grafting compared with medical therapy in ischaemic cardiomyopathy. Open Heart 2018, 5: e000752. PMID: 29531766, PMCID: PMC5845417, DOI: 10.1136/openhrt-2017-000752.Peer-Reviewed Original ResearchCoronary artery bypass surgeryIschemic left ventricular dysfunctionLeft ventricular dysfunctionWalk distanceVentricular dysfunctionMedical therapyMED groupFunctional capacityNew York Heart Association classSix-minute walk distanceMin walk distanceCoronary artery bypassArtery bypass surgeryVentricular ejection fractionCoronary artery diseaseArtery bypassBypass surgeryArtery diseaseAssociation classEjection fractionIschemic cardiomyopathySurgical treatmentTreatment allocationDisease trialsPatients